Oncaspar
(Pegaspargase)Phase 3Protein / enzyme
Pegaspargase is used to treat certain types of blood cancer, particularly acute lymphoblastic leukemia (ALL), by helping to kill cancer cells. It works by depleting an amino acid that leukemia cells need to survive.[1] Oncaspar is currently being investigated across 13 indications[3], with its most advanced program in Phase 3.[1]
Oncaspar is one of 216 small molecule programs targeting T-cell acute lymphoblastic leukemia. It is currently in Phase 3.
13
Indications
97
Total Trials
29
Active Trials
215
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 13 indications
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Oncaspar
SServier
Phase 3
Blenoxane
SSequus Pharmaceuticals
Preclinical
Zofran
NovartisPreclinical
Wellcovorin
GGlaxo Dba Glaxosmithkline
Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Rhg-CSF
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preclinical
CAR-T
HHebei Senlang Biotechnology Inc., Ltd.
Preclinical
JY231
SShenzhen Genocury Biotech Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia49 trials
Show 46 more trials
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Active, not recruiting·—·Phase 3·NCT03020030·560 enrolled
05-001: Treatment of Acute Lymphoblastic Leukemia in Children
Completed·—·Phase 3·NCT00400946·800 enrolled
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
Recruiting·—·Phase 1·NCT05157971·24 enrolled
Lymphoma15 trials
Show 12 more trials
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
Recruiting·—·Phase 1/2·NCT06376721·43 enrolled
GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
Unknown status·—·Phase 2·NCT04917250·15 enrolled
T-cell acute lymphoblastic leukemia4 trials
B Acute Lymphoblastic Leukemia4 trials
16 more indications
Children2 trials
Anti-PD-1 Antibody2 trials
Treatment2 trials
Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL
Unknown status·—·Phase 2·NCT04337593·20 enrolled
L-DEP as an Initial Treatment for EBV-HLH
Unknown status·—·Phase 3·NCT02912702·120 enrolled
Chidamide2 trials
Leukemia2 trials
Relapsed/Refractory1 trial
GPED Regimen for Relapsed/Refractory or Advanced ENKTCL
Unknown status·—·Phase 2·NCT04405375·29 enrolled
Precursor B-Cell Acute Lymphoblastic Leukemia1 trial
Relapsed/Refractory B-cell ALL1 trial
Histiocytosis1 trial
L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis
Unknown status·—·Phase 3·NCT02631109·120 enrolled
Blinatumomab1 trial
Lymphoblastic Lymphoma1 trial
Relapsed or Refractory1 trial
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
Terminated·—·Phase 2·NCT02535806·2 enrolled
Regulatory
FDA Approval Timeline[4]
Feb 1, 1994
ONCASPAR
BLA BLA103411
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pegaspargase. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]